Navigation Links
Astellas Seeks Rigorous Testing and Safety-Related Labeling for Anti-Rejection Medications
Date:8/10/2009

art transplant patients (15%) compared with cyclosporine-treated patients. Seizures have occurred in adult and pediatric patients receiving Prograf. Coma and delirium also have been associated with high plasma concentrations of tacrolimus.

In post marketing experience, patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). If PRES is suspected or diagnosed, immediate reduction of immunosuppression is advised. Activation of latent viral infections, including BK virus-associated nephropathy and JC virus-associated progressive multifocal leukoencephalopathy (PML), has also been reported. These viral infections may lead to serious, including fatal, outcomes.

The principal adverse reactions of Prograf include tremor, headache, hypertension, gastrointestinal disturbance, abnormal renal function, hyperglycemia, leukopenia, CMV infection, infection, and hyperlipemia.

For full prescribing information please visit www.prograf.com or call Astellas at 1-800-727-7003.

About Astellas Pharma US, Inc.

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at www.us.astellas.com.


'/>"/>
SOURCE Astellas Pharma US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas Announces New Vice President of Marketing
6. Astellas Hires New Vice President of Compliance
7. Astellas Adds CNS Therapy Area Leader to Global R&D Team
8. Astellas Names Head of Global R&D Operations
9. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
10. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
11. Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... has been a sharp increase in the number of ... the online, interactive service that allows patients to view ... schedule appointments, and renew prescriptions. , Over a six-year ... each year increased five-fold, while the number of ... to a study by Dr. David Gerber , ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
(Date:7/9/2014)... , , , , , ... , , , , ... an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... ... company, now offers their clients a choice between a Flat Fee Plan and a Monthly ... Miami, FL ... cash strapped plaintiffs don’t have to wait for their lawsuits to recover, they can get ...
... NASHVILLE, Tenn., Dec. 10 Pathological gambling can be ... inhibitions, according to researchers at the annual meeting of ... outcomes in gamblers treated with medications often used for ... his team at the University of Minnesota used tasks ...
... The 2009 American College of Neuropsychopharmacology Annual Meeting ... schizophrenia and treatment for gambling addiction. Study highlights ... Techniques to Assess PTSD. Working with Iraq and ... may be useful to evaluate PTSD and develop ...
... ... a leading neurologist, Dr. Alexander Mauskop, renowned headache expert and founder of the New ... ... 9, 2009 -- A powerful headache medicine developed by a leading neurologist for his ...
... , WARRINGTON, Pa., Dec. 9 Last year Special Equestrians was ... part of $25,000 in PR service grants. "We,ve always taken corporate ... a warm and fuzzy feeling to do what little we can ... co-founder, Christopher L. Simmons. "We learned many years ago that it ...
... Award Will Create New Construction and Permanent Jobs in the South ... Additional 12,000 Residents , NEW YORK, Dec. 9 ... Reinvestment Act (Recovery Act) grant to support a new addition to ... announced by President Barack Obama as part of his plan to ...
Cached Medicine News:Health News:Injury Funds Now To the Rescue with New Lawsuit Funding Service 2Health News:Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction 2Health News:Late-breaking brain and behavior research presented at ACNP annual meeting this week 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 2Health News:Breakthrough Approach to Age-old Ailment, Renowned Doctor Introduces Powerful Headache Medicine 3Health News:Nonprofit Partners With PR Company and Gains International Attention 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 2Health News:$12 Million American Recovery and Reinvestment Act Grant Awarded to Urban Health Plan, Inc. (UHP) 3
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Feb. 24, 2011 HeartWare International, Inc. (Nasdaq: ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... of $20.9 million for the fourth quarter ended December ... for the fourth quarter of 2009, and revenues of ...
... N.J. and EMERYVILLE, Calif., Feb. 24, 2011 ... ONXX ) today announced the companies ... randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets ... versus placebo plus capecitabine for the treatment of ...
Cached Medicine Technology:HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 2HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 3HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 4HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 5HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 2Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 3Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 4Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 5Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 7
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: